HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauder's Jane Restructuring Effort Involves $16 Mil. Charge In Q4

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder will take a one-time $16 mil. charge in the fiscal fourth quarter (ended June 30) for a restructuring effort aimed at boosting sales and profits for its jane brand of mass market cosmetics, President and CEO Fred Langhammer said during a conference call June 28.

You may also be interested in...



Jane Cosmetics Owners Seek Growth Through Expanded Distribution

Jane & Company aims to build the jane mass market cosmetics brand by recapturing retailers that have shied away from the line in recent years, according to President and CEO Lisa Yarnell. The newly-formed company announced the purchase of jane from Estee Lauder Feb. 9

Jane Cosmetics Owners Seek Growth Through Expanded Distribution

Jane & Company aims to build the jane mass market cosmetics brand by recapturing retailers that have shied away from the line in recent years, according to President and CEO Lisa Yarnell. The newly-formed company announced the purchase of jane from Estee Lauder Feb. 9

Lauder Exits Mass Market Jungle With Decision To Sell Jane

Estee Lauder's decision to sell its mass market teen cosmetics brand jane reflects the company's desire to focus on the mid-tier and prestige beauty markets, CEO Fred Langhammer stated, announcing the decision Jan. 29 during a sales and earnings call

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel